{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:58:22Z","timestamp":1775678302862,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015453","name":"Adamas Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40120-021-00256-1","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T18:02:28Z","timestamp":1621706548000},"page":"739-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson\u2019s Disease and Dyskinesia"],"prefix":"10.1007","volume":"10","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamal H.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kremens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Chernick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea E.","family":"Formella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"1","key":"256_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","volume":"58","author":"RA Hauser","year":"2019","unstructured":"Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58(1):77\u201388. https:\/\/doi.org\/10.1007\/s40262-018-0663-4.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"256_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. 2017;74(8):941\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0943.","journal-title":"JAMA Neurol"},{"issue":"12","key":"256_CR3","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. 2017;32(12):1701\u20139. https:\/\/doi.org\/10.1002\/mds.27131.","journal-title":"Mov Disord"},{"issue":"16","key":"256_CR4","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.22341","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008;23(16):2398\u2013403. https:\/\/doi.org\/10.1002\/mds.22341.","journal-title":"Mov Disord"},{"key":"256_CR5","unstructured":"Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson\u2019s disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M, editors. Recent developments in Parkinson\u2019s disease, vol 2. Florham Park: Macmillan Health Care Information; 1987. p. 153\u201363, 293\u2013304."},{"issue":"4","key":"256_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/mdc3.12462","volume":"4","author":"C Rodriguez-Blazquez","year":"2017","unstructured":"Rodriguez-Blazquez C, Alvarez M, Arakaki T, Campos Arillo V, Chana P, Fernandez W, et al. Self-assessment of disability in Parkinson\u2019s disease: the MDS-UPDRS part II versus clinician-based ratings. Mov Disord Clin Pract. 2017;4(4):529\u201335. https:\/\/doi.org\/10.1002\/mdc3.12462.","journal-title":"Mov Disord Clin Pract"},{"issue":"15","key":"256_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"issue":"2","key":"256_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O\u2019Brien CF, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol"},{"key":"256_CR9","unstructured":"Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale. Milwaukee: Movement Disorder Society; 2019. https:\/\/www.movementdisorders.org\/MDS-Files1\/PDFs\/Rating-Scales\/MDS-UPDRS_English_FINAL_Updated_August2019.pdf."},{"issue":"5","key":"256_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horvath","year":"2017","unstructured":"Horvath K, Aschermann Z, Kovacs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of Movement Disorder Society-sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32(5):789\u201393. https:\/\/doi.org\/10.1002\/mds.26960.","journal-title":"Mov Disord"},{"issue":"4","key":"256_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-018-0510-z","volume":"32","author":"LW Elmer","year":"2018","unstructured":"Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, et al. Author correction to: Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease. CNS Drugs. 2018;32(4):399\u2013400. https:\/\/doi.org\/10.1007\/s40263-018-0510-z.","journal-title":"CNS Drugs"},{"issue":"4","key":"256_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40263-018-0498-4","volume":"32","author":"LW Elmer","year":"2018","unstructured":"Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, et al. Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease. CNS Drugs. 2018;32(4):387\u201398. https:\/\/doi.org\/10.1007\/s40263-018-0498-4.","journal-title":"CNS Drugs"},{"key":"256_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00246-3","author":"SH Mehta","year":"2021","unstructured":"Mehta SH, Pahwa R, Tanner CM, Hauser RA, Johnson R. Effects of Gocovri (amantadine) extended release capsules on non-motor symptoms in patients with Parkinson\u2019s disease and dyskinesia. Neurology and Therapy. 2021. https:\/\/doi.org\/10.1007\/s40120-021-00246-3 (Epub ahead of print. PMID: 33864229).","journal-title":"Neurology and Therapy."},{"issue":"10","key":"256_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.parkreldis.2013.05.017","volume":"19","author":"C Rodriguez-Blazquez","year":"2013","unstructured":"Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(10):889\u201393. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.05.017.","journal-title":"Parkinsonism Relat Disord"},{"key":"256_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.parkreldis.2018.09.005","volume":"60","author":"R Pahwa","year":"2019","unstructured":"Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R, et al. Impact of dyskinesia on activities of daily living in Parkinson\u2019s disease: results from pooled phase 3 ADS-5102 clinical trials. Parkinsonism Relat Disord. 2019;60:118\u201325. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.09.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"256_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/practneurol-2013-000743","volume":"14","author":"Y Okuma","year":"2014","unstructured":"Okuma Y. Practical approach to freezing of gait in Parkinson\u2019s disease. Pract Neurol. 2014;14(4):222\u201330. https:\/\/doi.org\/10.1136\/practneurol-2013-000743.","journal-title":"Pract Neurol"},{"issue":"5","key":"256_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/nmt-2016-0018","volume":"6","author":"A Cucca","year":"2016","unstructured":"Cucca A, Biagioni MC, Fleisher JE, Agarwal S, Son A, Kumar P, et al. Freezing of gait in Parkinson\u2019s disease: from pathophysiology to emerging therapies. Neurodegener Dis Manag. 2016;6(5):431\u201346. https:\/\/doi.org\/10.2217\/nmt-2016-0018.","journal-title":"Neurodegener Dis Manag"},{"issue":"6","key":"256_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11910-013-0350-7","volume":"13","author":"E Heremans","year":"2013","unstructured":"Heremans E, Nieuwboer A, Vercruysse S. Freezing of gait in Parkinson\u2019s disease: where are we now? Curr Neurol Neurosci Rep. 2013;13(6):350. https:\/\/doi.org\/10.1007\/s11910-013-0350-7.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"suppl 2","key":"256_CR19","doi-asserted-by":"publisher","first-page":"S482","DOI":"10.1002\/mds.21914","volume":"23","author":"N Giladi","year":"2008","unstructured":"Giladi N. Medical treatment of freezing of gait. Mov Disord. 2008;23(suppl 2):S482\u20138. https:\/\/doi.org\/10.1002\/mds.21914.","journal-title":"Mov Disord"},{"issue":"6","key":"256_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/WNF.0b013e31826e3406","volume":"35","author":"R Malkani","year":"2012","unstructured":"Malkani R, Zadikoff C, Melen O, Videnovic A, Borushko E, Simuni T. Amantadine for freezing of gait in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):266\u20138. https:\/\/doi.org\/10.1097\/WNF.0b013e31826e3406.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"256_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","volume":"5","author":"NJ Diederich","year":"2009","unstructured":"Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5(6):331\u201342. https:\/\/doi.org\/10.1038\/nrneurol.2009.62.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"256_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996\u20131001. https:\/\/doi.org\/10.1001\/archneurol.2010.166.","journal-title":"Arch Neurol"},{"issue":"7","key":"256_CR23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.25003","volume":"27","author":"AH Lee","year":"2012","unstructured":"Lee AH, Weintraub D. Psychosis in Parkinson\u2019s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord. 2012;27(7):858\u201363. https:\/\/doi.org\/10.1002\/mds.25003.","journal-title":"Mov Disord"},{"issue":"3","key":"256_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3233\/JPD-171134","volume":"7","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 2 Study): interim results of an open-label safety study. J Parkinsons Dis. 2017;7(3):511\u201322. https:\/\/doi.org\/10.3233\/JPD-171134.","journal-title":"J Parkinsons Dis"},{"issue":"24","key":"256_CR25","doi-asserted-by":"publisher","first-page":"e2238","DOI":"10.1212\/WNL.0000000000006643","volume":"91","author":"P Turcano","year":"2018","unstructured":"Turcano P, Mielke MM, Bower JH, Parisi JE, Cutsforth-Gregory JK, Ahlskog JE, et al. Levodopa-induced dyskinesia in Parkinson disease: a population-based cohort study. Neurology. 2018;91(24):e2238\u201343. https:\/\/doi.org\/10.1212\/WNL.0000000000006643.","journal-title":"Neurology"},{"issue":"2","key":"256_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mdc3.12595","volume":"5","author":"SH Isaacson","year":"2018","unstructured":"Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, et al. Parkinson\u2019s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102. Mov Disord Clin Pract. 2018;5(2):183\u201390. https:\/\/doi.org\/10.1002\/mdc3.12595.","journal-title":"Mov Disord Clin Pract"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00256-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T13:25:56Z","timestamp":1636118756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00256-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00256-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}